177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Neuroendocrine Tumors
Related studies linked through entity extraction aliases.
A Study to Assess Neuroendocrine Tumour (NET) Patients Currently Treated by Somatuline Autogel for History of Carcinoid Syndrome Associated With Episodes of Diarrhea
- Status
- COMPLETED
- Phase
- N/A
Study of Everolimus (RAD001) in Combination With Lenalidomide
- Status
- COMPLETED
- Phase
- PHASE1
Predictive Biomarkers of Response to Sunitinib in the Treatment of Poorly-differentiated NEURO-Endocrine Tumors
- Status
- TERMINATED
- Phase
- PHASE2
Neo-adjuvant Peptide Receptor Mediated Radiotherapy With 177Lutetium in Front of Curative Intended Liver Transplantation in Patients With Hepatic Metastasis of Neuroendocrine Tumors (NEO-LEBE)
- Status
- UNKNOWN
- Phase
- N/A
Safety and Tolerability Profile of RAD001 Daily in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Perfusion CT as a Predictor of Treatment Response in Patients With Hepatic Malignancies
- Status
- TERMINATED
- Phase
- N/A
B-Receptor Signaling in Cardiomyopathy
- Status
- COMPLETED
- Phase
- N/A
A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1
Combination Targeted Radiotherapy in Neuroendocrine Tumors
- Status
- COMPLETED
- Phase
- NA
SwissNET - a Registry for Neuroendocrine Tumours in Switzerland
- Status
- RECRUITING
- Phase
- N/A
Study of Panobinostat in Patients With Neuroendocrine Tumors
- Status
- TERMINATED
- Phase
- PHASE2
DOTA-TOC in Metastasized Neuroendocrine Tumors
- Status
- COMPLETED
- Phase
- PHASE2
5FU and Octreotide Long-acting Release (LAR) for Neuroendocrine Tumors
- Status
- COMPLETED
- Phase
- PHASE2
A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors
- Status
- TERMINATED
- Phase
- PHASE2
Follow Up Protocol for Subjects Previously Enrolled on NCI Surgery Branch Studies
- Status
- ENROLLING_BY_INVITATION
- Phase
- N/A
Capecitabine and Temozolomide for Neuroendocrine Cancers
- Status
- COMPLETED
- Phase
- PHASE2
ProGRP, CgA, NSE and TUM2-PK in in Patients With Neuroendocrine Tumors
- Status
- UNKNOWN
- Phase
- N/A
RAD001 and Erlotinib in Patients With Neuroendocrine Tumors
- Status
- TERMINATED
- Phase
- PHASE2
Best Therapy for Patients With Neuroendocrine Tumors
- Status
- COMPLETED
- Phase
- N/A